Double trouble for triple-negative breast cancer: Two-pronged strategy restores immunotherapy sensitivity

by Kimberly McGhee,Medical University of South CarolinaTumor-fighting immune cells in the tumor before (left) and after (right) combination therapy. After combination therapy, many more tumor-fi

Updated on: September 27,2024 0

Double trouble for triple-negative breast cancer: Two-pronged strategy restores immunotherapy sensitivity

by Kimberly McGhee,Medical University of South CarolinaTumor-fighting immune cells in the tumor before (left) and after (right) combination therapy. After combination therapy, many more tumor-fi

Updated on:September 27,2024 0

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an accepta

Updated on: September 27,2024 0

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an accepta

Updated on:September 27,2024 0

Improving transplant success and single cell analysis revealing cell state changes in prostate cancer

byMemorial Sloan Kettering Cancer CenterAn MSK scientist works in the lab. Credit: Memorial Sloan Kettering Cancer CenterNew research from Memorial Sloan Kettering Cancer Center (MSK) showed giv

Updated on: August 27,2024 0

Improving transplant success and single cell analysis revealing cell state changes in prostate cancer

byMemorial Sloan Kettering Cancer CenterAn MSK scientist works in the lab. Credit: Memorial Sloan Kettering Cancer CenterNew research from Memorial Sloan Kettering Cancer Center (MSK) showed giv

Updated on:August 27,2024 0

Combination treatment improves survival in advanced prostate cancer with genetic mutations

by Melissa Rohman,Northwestern UniversityProstate cancer cells. Credit: NIH Image GalleryA combination therapy improved progression-free survival in patients with metastatic castration-resistant

Updated on: September 30,2024 0

Combination treatment improves survival in advanced prostate cancer with genetic mutations

by Melissa Rohman,Northwestern UniversityProstate cancer cells. Credit: NIH Image GalleryA combination therapy improved progression-free survival in patients with metastatic castration-resistant

Updated on:September 30,2024 0

Daily aspirin cuts odds for colon cancer: who benefits most?

by Ernie MundellIt's long been known that a daily dose of low-dose aspirin helps keepcolon cancerat bay.But new research suggests that those who benefit most are folks whose lifestyles

Updated on: August 27,2024 0

Daily aspirin cuts odds for colon cancer: who benefits most?

by Ernie MundellIt's long been known that a daily dose of low-dose aspirin helps keepcolon cancerat bay.But new research suggests that those who benefit most are folks whose lifestyles

Updated on:August 27,2024 0

Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in some patients

by International Association for the Study of Lung CancerCredit: Unsplash/CC0 Public DomainThe combination of osimertinib and savolitinib showed clinically meaningful improvement in objective response

Updated on: September 27,2024 0

Osimertinib with savolitinib demonstrates stronger efficacy than osimertinib alone in some patients

by International Association for the Study of Lung CancerCredit: Unsplash/CC0 Public DomainThe combination of osimertinib and savolitinib showed clinically meaningful improvement in objective response

Updated on:September 27,2024 0

First-of-its-kind tool to check potential inherited risk of pancreatic cancer launches

byUniversity of LiverpoolCredit: Unsplash/CC0 Public DomainFamilies who have been affected by pancreatic cancer can assess their risk of inheriting the disease through a new first-of-its-kind&nb

Updated on: September 30,2024 0

First-of-its-kind tool to check potential inherited risk of pancreatic cancer launches

byUniversity of LiverpoolCredit: Unsplash/CC0 Public DomainFamilies who have been affected by pancreatic cancer can assess their risk of inheriting the disease through a new first-of-its-kind&nb

Updated on:September 30,2024 0

Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutations

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung can

Updated on: September 27,2024 0

Trial demonstrates firmonertinib is a potential therapy for patients with NSCLC with EGFR PACC mutations

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe tyrosine kinase inhibitor firmonertinib showed promising efficacy in patients with non-small cell lung can

Updated on:September 27,2024 0

Study shows INT-1B3 inhibits distant tumor metastasis and significantly prolongs survival

by Impact Journals LLCProposed mode of action of INT-1B3/1B3.INT-1B3/1B3 induces apoptosis and cell death leading to expression of DAMPs, e.g., expression of calreticulin, reduced expression of CD39 a

Updated on: August 27,2024 0

Study shows INT-1B3 inhibits distant tumor metastasis and significantly prolongs survival

by Impact Journals LLCProposed mode of action of INT-1B3/1B3.INT-1B3/1B3 induces apoptosis and cell death leading to expression of DAMPs, e.g., expression of calreticulin, reduced expression of CD39 a

Updated on:August 27,2024 0

Long-term conditions could delay lung cancer diagnosis, new study finds

byUniversity of SussexMedian diagnostic interval by number of AE and CD conditions. Credit:British Journal of Cancer(2024). DOI: 10.1038/s41416-024-02824-2A new study from researcher

Updated on: September 07,2024 0

Long-term conditions could delay lung cancer diagnosis, new study finds

byUniversity of SussexMedian diagnostic interval by number of AE and CD conditions. Credit:British Journal of Cancer(2024). DOI: 10.1038/s41416-024-02824-2A new study from researcher

Updated on:September 07,2024 0

Preclinical study shows promise of systemic targeted therapy in a rare form of cancer

byVall d'Hebron Institute of OncologyTreatment with BRAF inhibitors reduces tumor cell proliferation in subcutaneous BRAFV600EPMP-PDX tumors without impacting in apoptosis. a–d) Mice b

Updated on: August 03,2024 0

Preclinical study shows promise of systemic targeted therapy in a rare form of cancer

byVall d'Hebron Institute of OncologyTreatment with BRAF inhibitors reduces tumor cell proliferation in subcutaneous BRAFV600EPMP-PDX tumors without impacting in apoptosis. a–d) Mice b

Updated on:August 03,2024 0

Study examines trends in esophageal cancer disparities over time

by Elana GotkineFrom 1999 to 2020, age-adjusted esophageal cancer mortality decreased among Black adults but stabilized among white adults, reducing the racial mortality gap, according to a study&nbsp

Updated on: August 27,2024 0

Study examines trends in esophageal cancer disparities over time

by Elana GotkineFrom 1999 to 2020, age-adjusted esophageal cancer mortality decreased among Black adults but stabilized among white adults, reducing the racial mortality gap, according to a study&nbsp

Updated on:August 27,2024 0